GFM
OBIO icon

GF Fund Management’s Orchestra BioMed OBIO Stock Holding History

GF Fund Management’s Portfolio OBIO Stock Details OBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$5.06K Sell
1,173
-87
-7% -$356 ﹤0.01% 571
2026
Q1 		$5.36K Buy
1,260
+151
+14% +$643 ﹤0.01% 604
2025
Q4 		$4.6K Buy
+1,109
New +$4.47K ﹤0.01% 625

Other funds holding OBIO

RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $38.9B AUM 28.51% 1-Year Est. Return
PBM
Propel Bio Management Los Angeles, California $191M AUM 102.42% 1-Year Est. Return
UBS AM
UBS AM Chicago, Illinois $550B AUM 43.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
RHJA
Rice Hall James & Associates San Diego, California $2.05B AUM 43.16% 1-Year Est. Return

GF Fund Management's OBIO Position: Q2 2026 in Review

GF Fund Management reduced its Orchestra BioMed (OBIO) stake by 6.9% in Q2 2026, selling an estimated $356 and leaving 1,173 shares worth $5.06K. The position accounts for ﹤0.01% of the portfolio, ranked #571.

GF Fund Management first reported a position in OBIO in Q4 2025 and has held it in 3 quarters since. The position peaked at $5.36K in Q1 2026. 77 funds tracked by Wall St. Rank hold OBIO as of Q2 2026.

  • GF Fund Management held 1,173 shares of Orchestra BioMed worth $5.06K as of Q2 2026.
  • GF Fund Management sold 87 Orchestra BioMed shares in Q2 2026, an estimated $356.
  • Orchestra BioMed made up ﹤0.01% of GF Fund Management's portfolio in Q2 2026, its #571 holding.
  • GF Fund Management first reported a position in Orchestra BioMed in Q4 2025 and has held it in 3 quarters since.
  • GF Fund Management's Orchestra BioMed position peaked at $5.36K in Q1 2026.
  • 77 funds tracked by Wall St. Rank held Orchestra BioMed as of Q2 2026.

Based on GF Fund Management's 13F filing for Q2 2026, filed 7 Aug 2026.